|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
6505.50
|
|
|
52-Week-Low (Rs.)
|
4383.40
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | UnAudited | Net Sales | 41,030.00 | 48,387.00 | 54,373.00 | 45,540.00 | Total Expenditure | 34,467.00 | 32,096.00 | 32,096.00 | 34,929.00 | PBIDT (Excl OI) | 6,563.00 | 16,291.00 | 22,277.00 | 10,611.00 | Other Income | 2,276.00 | 2,231.00 | 2,336.00 | 1,148.00 | Operating Profit | 8,839.00 | 18,522.00 | 24,613.00 | 11,759.00 | Interest | 56.00 | 58.00 | 45.00 | 26.00 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 8,783.00 | 18,464.00 | 24,568.00 | 11,733.00 | Depreciation | 2,464.00 | 2,458.00 | 2,372.00 | 2,367.00 | Profit Before Tax | 6,319.00 | 16,006.00 | 22,196.00 | 9,366.00 | Tax | 1,567.00 | 4,080.00 | 5,802.00 | 2,642.00 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 4,752.00 | 11,926.00 | 16,394.00 | 6,724.00 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 4,752.00 | 11,926.00 | 16,394.00 | 6,724.00 | Equity Capital | 834.00 | 834.00 | 833.00 | 833.00 | Face Value (IN RS) | 5 | 5 | 5 | 5 | Reserves | | | | | Calculated EPS | 28.49 | 71.50 | 98.40 | 40.36 | Calculated EPS (Annualised) | 113.96 | 286.00 | 393.61 | 161.44 | No of Public Share Holdings | 96,772,670.00 | 98,945,802.00 | 101,208,665.00 | 103,244,559.00 | % of Public Share Holdings | 58.02 | 59.32 | 60.76 | 62.00 | | | | | | PBIDTM% (Excl OI) | 16.00 | 33.67 | 40.97 | 23.30 | PBIDTM% | 21.54 | 38.28 | 45.27 | 25.82 | PBDTM% | 21.41 | 38.16 | 45.18 | 25.76 | PBTM% | 15.40 | 33.08 | 40.82 | 20.57 | PATM% | 11.58 | 24.65 | 30.15 | 14.77 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|